Delcath Systems (DCTH) Expected to Announce Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is anticipated to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Delcath Systems to post earnings of ($0.10) per share and revenue of $14.96 million for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Delcath Systems Stock Down 5.8 %

Shares of DCTH stock opened at $13.35 on Tuesday. The business has a 50-day moving average price of $14.28 and a two-hundred day moving average price of $11.56. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $16.97. The firm has a market cap of $426.85 million, a P/E ratio of -9.89 and a beta of 0.86.

Analyst Ratings Changes

Several brokerages have issued reports on DCTH. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday, January 14th. Craig Hallum lifted their price target on Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.